also reported a novel metabolic reprogramming-based cisplatin-resistance mechanism in NSCLC cells involving increased PGC-1α expression, oxidative metabolism, and mitochondrial biogenesis (152). The gene discussed is PPARGC1A; the disease is non-small cell lung carcinoma.